Amlodipine & Atenolol is indicated in:

• Hypertension not controlled by monotherapy
• Angina pectoris & hypertension co-existing diseases
• Post MI patients
• Refractory angina pectoris where nitrate therapy has failed

Amlodipine is a dihydropyridine calcium antagonist that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle; it has a greater effect on vascular muscle than on cardiac muscle. Amlodipine is a peripheral vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure. Amlodipine reduces tone, decreases coronary vasoreactivity and lowers cardiac demand by reducing afterload.

Atenolol is a cardio selective beta blocker. The cardio selectivity is dose related. Atenolol causes a reduction in blood pressure by lowering cardiac output, decreasing the plasma renin activity and sympathetic outflow from CNS. Atenolol also causes a reduction in myocardial oxygen demand by virtue of its negative inotropic and negative chronotropic effects.

Amlodipine has been safely administered with thiazide diuretics, beta blockers, alpha blockers, angiotensin converting enzyme inhibitors, long-acting nitrates, sublingual glyceryl trinitrate, non-steroidal anti-inflammatory agents, antibiotics, and oral hypoglycemic agents. In vitro data from studies with human plasma indicate that amlodipine has no effect on protein binding of the drugs tested (Digoxin, Phenytoin, Warfarin, or Indomethacin).

Atenolol reduces the clearance of Disopyramide by 20%. Additive negative inotropic effects on the heart may be produced. At doses of 1 gm and above, Ampicillin may reduce Atenolol levels. Beta-blockers may decrease tissue sensitivity to Insulin and inhibit Insulin secretion, e.g. in response to oral antidiabetics. Atenolol has less potential for these actions.